Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$20.88 - $35.19 $3.5 Million - $5.9 Million
-167,658 Reduced 70.84%
69,030 $2.03 Million
Q1 2022

May 13, 2022

SELL
$29.0 - $47.27 $1.65 Million - $2.69 Million
-56,866 Reduced 19.37%
236,688 $7.61 Million
Q4 2021

Feb 14, 2022

BUY
$42.59 - $55.02 $609,037 - $786,786
14,300 Added 5.12%
293,554 $13.1 Million
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $3.37 Million - $5.44 Million
69,556 Added 33.17%
279,254 $14.1 Million
Q2 2021

Aug 13, 2021

BUY
$50.3 - $78.44 $3.52 Million - $5.49 Million
70,000 Added 50.11%
209,698 $16.4 Million
Q1 2021

May 14, 2021

SELL
$53.8 - $81.53 $8.12 Million - $12.3 Million
-151,000 Reduced 51.94%
139,698 $7.98 Million
Q4 2020

Feb 12, 2021

BUY
$36.89 - $93.56 $9.77 Million - $24.8 Million
264,710 Added 1018.59%
290,698 $24.3 Million
Q3 2020

Nov 12, 2020

BUY
$23.13 - $38.84 $601,102 - $1.01 Million
25,988 New
25,988 $931,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.